{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:51:10Z","timestamp":1785189070657,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.esmoop.2023.100884","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T12:06:19Z","timestamp":1677585979000},"page":"100884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-4157","authenticated-orcid":false,"given":"J.R.","family":"Hecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.S.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2135-2286","authenticated-orcid":false,"given":"A.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3113-7902","authenticated-orcid":false,"given":"K.","family":"Kalinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4876-4600","authenticated-orcid":false,"given":"J.-F.","family":"Baurain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5891-3935","authenticated-orcid":false,"given":"M.M.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9224-7104","authenticated-orcid":false,"given":"M.D.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.M.","family":"Lauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Khattak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7749-8140","authenticated-orcid":false,"given":"A.","family":"Carrato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0789-4970","authenticated-orcid":false,"given":"Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8172-0656","authenticated-orcid":false,"given":"E.","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5560-9989","authenticated-orcid":false,"given":"A.","family":"Keegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bhatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.P.","family":"Strassburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Roohullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.esmoop.2023.100884_bib1","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-15-2667","article-title":"Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy","volume":"22","author":"Kohlhapp","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.esmoop.2023.100884_bib2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/sj.gt.3301885","article-title":"ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties","volume":"10","author":"Liu","year":"2003","journal-title":"Gene Ther"},{"key":"10.1016\/j.esmoop.2023.100884_bib3","unstructured":"IMLYGIC\u00ae (talimogene laherparepvec). Full Prescribing Information. Thousand Oaks, CA: Amgen Inc; 2023. Available at imlygic_pi.ashx (amgen.com). Accessed February 22, 2023."},{"key":"10.1016\/j.esmoop.2023.100884_bib4","unstructured":"IMLYGICTM. Summary of Product Characteristics. London, UK: European Medicines Agency; 2020. Available at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/imlygic-epar-product-information_en.pdf. Accessed February 22, 2023."},{"key":"10.1016\/j.esmoop.2023.100884_bib5","unstructured":"TECENTRIQ (Atezolizumab). Full Prescribing Information. South San Francisco, CA: Genentech Inc.; 2022. Available at tecentriq_prescribing.pdf (gene.com). Accessed February 22, 2023."},{"key":"10.1016\/j.esmoop.2023.100884_bib6","unstructured":"European Medicines Evaluation Agency. Tecentriq: summary of product characteristics. Available at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecentriq-epar-product-information_en.pdf. Accessed February 16, 2023."},{"issue":"22","key":"10.1016\/j.esmoop.2023.100884_bib7","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2023.100884_bib8","unstructured":"Roche. Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer. Available at https:\/\/www.roche.com\/media\/releases\/med-cor-2021-08-27.htm. Accessed September 14, 2021."},{"issue":"8","key":"10.1016\/j.esmoop.2023.100884_bib9","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2023.100884_bib10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","article-title":"Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study","volume":"5","author":"Emens","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2023.100884_bib11","unstructured":"OPDIVO (Nivolumab). Full Prescribing Information. Princeton, NJ: Bristol-Myers Squibb Company; 2022. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125554s112lbl.pdf. Accessed February 17, 2023."},{"key":"10.1016\/j.esmoop.2023.100884_bib12","unstructured":"KEYTRUDA (Pembrolizumab). Full Prescribing Information. Whitehouse Station, NJ: Merck & Co., Inc.; 2023. Available at https:\/\/www.keytrudahcp.com\/prescribing-information\/. Accessed February 16, 2023."},{"key":"10.1016\/j.esmoop.2023.100884_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820917527","article-title":"Advances in immunotherapy for colorectal cancer: a review","volume":"13","author":"Golshani","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"issue":"6","key":"10.1016\/j.esmoop.2023.100884_bib14","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1158\/2159-8290.CD-21-0521","article-title":"PD-1 blockade in solid tumors with defects in polymerase epsilon","volume":"12","author":"Rousseau","year":"2022","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.esmoop.2023.100884_bib15","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2023.100884_bib16","doi-asserted-by":"crossref","first-page":"S868","DOI":"10.1016\/j.annonc.2021.08.1422","article-title":"MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage III-IVM1c melanoma (MEL)","volume":"32","author":"Ribas","year":"2021","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1016\/j.esmoop.2023.100884_bib17","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2023.100884_bib18","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/01.sla.0000217629.94941.cf","article-title":"Epidemiology and management of liver metastases from colorectal cancer","volume":"244","author":"Manfredi","year":"2006","journal-title":"Ann Surg"},{"issue":"10","key":"10.1016\/j.esmoop.2023.100884_bib19","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/cncr.23930","article-title":"Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases","volume":"113","author":"Lin","year":"2008","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2023.100884_bib20","doi-asserted-by":"crossref","first-page":"931","DOI":"10.5858\/2008-132-931-MPOCRF","article-title":"Metastatic patterns of cancers: results from\u00a0a\u00a0large autopsy study","volume":"132","author":"Disibio","year":"2008","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.esmoop.2023.100884_bib21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.esmoop.2023.100884_bib22","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3390\/v13061128","article-title":"Oncolytic virotherapy treatment of breast cancer: barriers and recent advances","volume":"13","author":"Kwan","year":"2021","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.esmoop.2023.100884_bib23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/biomedicines5010011","article-title":"Viroimmunotherapy for colorectal cancer: clinical studies","volume":"5","author":"Chaurasiya","year":"2017","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.esmoop.2023.100884_bib24","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10549-017-4538-4","article-title":"A\u00a0randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213","volume":"167","author":"Bernstein","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2023.100884_bib25","article-title":"Abstract OT-13-02: Bracelet-1 (pre0113): a study to assess overall response rate by inducing an inflammatory phenotype in metastatic breast cancer with the oncolytic reovirus pelareorep in combination with anti-PD-L1 avelumab and paclitaxel","volume":"81","author":"Miller","year":"2021","journal-title":"Cancer Res"},{"issue":"suppl","key":"10.1016\/j.esmoop.2023.100884_bib26","article-title":"A\u00a0phase 1b\/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into primary and metastatic liver tumors alone and in combination with pembrolizumab (pembro) (MASTERKEY-318)","volume":"36","author":"Hecht","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2023.100884_bib27","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3390\/cancers13061383","article-title":"Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma","volume":"13","author":"Ferrucci","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2023.100884_bib28","unstructured":"ClinicalTrials.gov. Single-arm trial to evaluate the role of the immune response to talimogene laherparepvec in unresected melanoma (TVEC-325) (NCT02366195). Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02366195?term=02366195&draw=2&rank=1. Accessed February 16, 2023."},{"issue":"9","key":"10.1016\/j.esmoop.2023.100884_bib29","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","article-title":"Intratumoural administration and tumour tissue targeting of cancer immunotherapies","volume":"18","author":"Melero","year":"2021","journal-title":"Nat Rev Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923001047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702923001047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:30:07Z","timestamp":1761856207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702923001047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S2059702923001047"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.100884","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2023.100884","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100884"}}